• lymphomas
  • CD30-positive malignant lymphomas: time for a change of management? (haematologica.org)
  • describe CD30 expression in peripheral T-cell lymphomas. (haematologica.org)
  • These data contribute to the growing body of evidence on a changing landscape in the treatment of CD30-positive malignant lymphomas. (haematologica.org)
  • 5 , 6 Shortly thereafter, CD30 was also found on the malignant cells of anaplastic large cell lymphoma (ALCL) and other malignant lymphomas. (haematologica.org)
  • Another paper published in this issue of the journal describes the molecular and phenotypic features common to CD30-positive peripheral T-cell lymphomas, and significant differences between CD30-negative and CD30-positive peripheral T-cell lymphomas, not otherwise specified, suggesting that CD30 expression might delineate two biologically distinct subgroups within this heterogeneous category. (haematologica.org)
  • The putative clinical relevance of these subgroups could be the potential benefits of incorporating anti-CD30 immunoconjugates into the treatment strategies of CD30-positive peripheral T-cell lymphomas, not otherwise specified. (haematologica.org)
  • Monoclonal antibodies (mAb) have proven to be an effective class of new antitumor agents for several tumor types and are especially useful in hematologic cancers such as leukemias and lymphomas. (aacrjournals.org)
  • Antibodies detecting hypoglycosylated MUC1 were found to be absent in all lymphomas (SM3) or present in only six of 15 ALK positive ALCLs (VU-4H5). (bmj.com)
  • Therefore, although MUC1 could be used in a panel of markers for CD30 positive lymphomas, it is probably not a valuable tool to differentiate between ALK negative CD30 positive large cell lymphomas. (bmj.com)
  • 7, 10, 12, 13 Morphologically, these lymphomas may closely resemble systemic ALCL, being also characterised by CD30 positive tumour cells with abundant cytoplasm, large irregular nuclei, and a prominent single nucleolus or multiple nucleoli. (bmj.com)
  • Several markers can be used in the differential diagnosis of ALCL and other CD30 positive lymphomas. (bmj.com)
  • First, we are interested in Epstein Barr Virus-mediated mechanisms of immune evasion with particular focus on pathways that promote survival and proliferation of EBV B cell lymphomas, the characterization of the human T cell response to EBV-infected B cells and the identification of novel therapeutics for treatment of EBV B cell lymphomas. (stanford.edu)
  • superfamily
  • The gene for LAG-3 lies adjacent to the gene for CD4 on human chromosome 12 (12p13) and is approximately 20% identical to the CD4 gene The LAG3 protein, which belongs to immunoglobulin (Ig) superfamily, comprises a 503-amino acid type I transmembrane protein with four extracellular Ig-like domains, designated D1 to D4. (wikipedia.org)
  • ligand
  • An initial characterization of the LAG-3 protein was reported in 1992 showing that it was a ligand for MHC class II antigens while a 1995 paper showed that it bound MHC Class II better than CD4. (wikipedia.org)
  • bispecific
  • Entwicklung und Charakterisierung bispezifischer Antikörper-Derivate zur Immuntherapie CD19-positiver Leukämien und Lymphome" [Development and characterisation of bispecific antibody derivatives for the immunotherapy of CD19-positive leukaemia and lymphoma] (in German and English). (wikipedia.org)
  • Soluble
  • Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response. (exbio.cz)
  • Incubation of CD30 positive L540 cells with Ki-3 antibody weakly enhances release of soluble CD30 (in contrast to Ki-4, Ab00475). (absoluteantibody.com)
  • The phenotype of LAG-3 knockout mice, as established by the INSERM Strasbourg group in 1996, demonstrated that LAG-3 was vital for the proper functioning of natural killer cells but in 1998 Triebel, working with LAG-3 antibodies and soluble protein, found that LAG-3 did not define a specific mode of natural killing. (wikipedia.org)
  • Western Blot
  • Abgent's experienced staff custom validates more than 1,000 antibodies each month in Western Blot (WB), Immunofluorescence (IF), Immunohistochemistry (IHC), Flow Cytometry (FC) and additional applications. (abgent.com)
  • mAbs
  • CD30 has therefore attracted attention as a potential target for immunotherapy of HL and ALCL, and several mAbs specific for CD30 have been developed and tested in the clinic with varying degrees of success ( 6 - 10 ). (aacrjournals.org)
  • brentuximab vedotin
  • Upon binding to the target antigen, brentuximab vedotin is internalized and subsequently degraded within the lysosomal compartment. (haematologica.org)
  • Brentuximab vedotin includes an enzyme-sensitive cleavable linker that delivers the potent and highly toxic antimicrotubule agent monomethyl auristatin E or MMAE, a synthetic antineoplastic agent, to human specific CD30-positive malignant cells. (wikipedia.org)
  • The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. (clinicaltrials.gov)
  • inhibit
  • LAG-3 may be a better checkpoint inhibitor target than CTLA-4 or PD-1 since antibodies to these two checkpoints only activate effector T cells, and do not inhibit Treg activity, whereas an antagonist LAG-3 antibody can both activate T effector cells (by downregulating the LAG-3 inhibiting signal into pre-activated LAG-3+ cells) and inhibit induced (i.e. antigen-specific) Treg suppressive activity. (wikipedia.org)
  • marker
  • In developing antibody-drug conjugates, an anticancer drug (e.g. a cell toxin or cytotoxin) is coupled to an antibody that specifically targets a certain tumor marker (e.g. a protein that, ideally, is only to be found in or on tumor cells). (wikipedia.org)
  • One such marker is MUC1 mucin, also known as epithelial membrane antigen (EMA). (bmj.com)
  • expression
  • In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. (exbio.cz)
  • CHO-Anti-Human CD30 F(ab) stable cell line is clonally-derived from a CHO cell line, which has been transfected with an anti-human CD30 F(ab) gene to allow expression of the F(ab). (creativebiomart.net)
  • Pluckthun and Skerra, Expression of Functional Antibody Fv and Fab Fragments in Escherichia coli. (freepatentsonline.com)
  • In May 1996 scientists at the University of Florence showed that CD4+ T cells that were LAG-3+ preferentially expressed IFN-γ, and this was up-regulated by IL-12 while in 1997 the same group showed that IFN-γ production was a driver of LAG-3 expression during the lineage commitment of human naive T cells. (wikipedia.org)
  • The Triebel group in 1998 established that LAG-3 expression on activated human T cells is upregulated by IL-2, IL-7 and IL-12 and also showed that expression of LAG-3 may be controlled by some CD4 regulatory elements. (wikipedia.org)
  • trastuzumab
  • Similar findings were made with clinically successful antibodies rituximab and trastuzumab, which had no detectable effect in mice lacking activating FcRs, but showed high levels of antitumor activity in mice deficient in inhibitory receptor FcγRIIB ( 14 ). (aacrjournals.org)
  • Trastuzumab emtansine, the other approved ADC, is a combination of the microtubule-formation inhibitor mertansine (DM-1), a derivative of the Maytansine, and antibody trastuzumab (Herceptin/ Genentech/Roche) attached by a stable, non-cleavable linker. (wikipedia.org)
  • therapeutic
  • Multiple approaches to enhance the efficacy of therapeutic antibodies, such as modification of glycosylation profiles, are currently being pursued by various biopharma companies. (aacrjournals.org)
  • More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function. (freepatentsonline.com)
  • Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene," Blood 99:754-758, American Society of Hematology (Feb. 2002). (freepatentsonline.com)
  • refractory
  • On August 17, 2017 Inotuzumab ozogamicin was also approved by the US FDA for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) A stable link between the antibody and cytotoxic (anti-cancer) agent is a crucial aspect of an ADC. (wikipedia.org)
  • novel
  • We provide tools for path-breaking research by developing antibodies that detect a comprehensive library of novel and established targets. (abgent.com)
  • cell
  • Crown antibodies pass additional stringent quality requirements, including extended control sets, uniform results against multiple biologically relevant cell lines and tissues, and function in multiple applications. (abgent.com)
  • It is also expressed on a subset of activated human T-cells, and by a few extrafollicular T and B-cell blasts in normal lymph nodes. (bio-rad-antibodies.com)
  • This means that, in contrast to traditional chemotherapeutic agents, antibody-drug conjugates target and attack the cancer cell so that healthy cells are less severely affected. (wikipedia.org)
  • The biochemical reaction between the antibody and the target protein (antigen) triggers a signal in the tumor cell, which then absorbs or internalizes the antibody together with the cytotoxin. (wikipedia.org)
  • Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones. (freepatentsonline.com)
  • Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning. (freepatentsonline.com)
  • inhibitor
  • Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, Law CL, Gerber HP (2008) Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. (springer.com)
  • The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6. (freepatentsonline.com)
  • potent
  • For example, an antimelanoma antibody with potent antitumor activity in a wild-type mouse model showed less efficacy in mice lacking activating FcγRI and FcγRIII ( 13 ). (aacrjournals.org)
  • Antibody-drug conjugates or ADCs are an important class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with cancer. (wikipedia.org)
  • purification
  • Each antibody is crafted with care according to rigorous protocols for immunogen design and preparation, presentation to host animal, and high-affinity purification against the antigen. (abgent.com)
  • Cancer
  • By combining the unique targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, antibody-drug conjugates allow sensitive discrimination between healthy and diseased tissue. (wikipedia.org)
  • Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blattler WA (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. (springer.com)
  • The second are antibodies to LAG3 which take the brakes off the anti-cancer immune response. (wikipedia.org)
  • cells
  • The reagent is designed for Flow Cytometry analysis of human blood cells using 10 μl reagent / 100 μl of whole blood or 10 6 cells in a suspension. (exbio.cz)
  • In this chapter, we review various linkers, cleavable and non-cleavable, that have been reported, main approaches that have been used to attach the linkers to the antibodies, and the impact of various linkers on the properties of the resulting ADCs, such as their cytotoxic and antitumor activities, stabilities in circulation and tissues, and the extent of killing of bystander cells and of multidrug-resistant cells. (springer.com)
  • Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor. (freepatentsonline.com)